Your session is about to expire
← Back to Search
Cabotegravir + Rilpivirine Injections for HIV/AIDS
Study Summary
This trial is testing whether an injection of two drugs every month can effectively suppress HIV in people who are already taking daily pills to control the virus.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My HIV treatment has been stable with approved drugs and minor changes.I need long-term blood thinners, with some exceptions.I am not currently taking any medications or have a treatment history that would exclude me.I have been on my current HIV medication for at least 6 months without changing it due to treatment failure.My HIV viral load has been mostly under control, with one or two increases.My medication was changed due to it not controlling my virus.My HIV treatment regimen has been stable before screening.My HIV viral load has been above 50 c/mL after initially being suppressed.I have not stopped my HIV treatment for more than a month, except for short breaks due to side effects.I am not pregnant, breastfeeding, nor planning to become pregnant or breastfeed during the study.I am 18 years old or older.I am not on any excluded ARV regimens.I am a woman who meets specific health criteria.I don't have any health issues that could affect my safety in the study.You have had at least two blood tests for HIV in the last year and both showed the virus was suppressed to very low levels.Your blood test shows that your HIV-1 viral load is less than 50 copies per milliliter at the start of the study.
- Group 1: Current antiretroviral regimen
- Group 2: CAB LA + RPV LA every 4 weeks
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other medical research has been completed with Cabotegravir - Injectable Suspension (CAB LA)?
"At the current moment, there are 21 ongoing clinical trials evaluating Cabotegravir - Injectable Suspension (CAB LA). Of these 21 active studies, 7 are in Phase 3. The majority of research on this topic is being conducted in Bronx, New york; however, there are 640 total locations running similar investigations."
What are the risks associated with Cabotegravir - Injectable Suspension (CAB LA)?
"Cabotegravir - Injectable Suspension (CAB LA) is a medication that has received a 3 for safety. This number comes from it being in Phase 3 of trials, where there is some evidence of its efficacy as well as multiple rounds of data supporting its safety."
What is Cabotegravir - Injectable Suspension (CAB LA) most often used as a remedy for?
"Cabotegravir - Injectable Suspension (CAB LA) is most often used to treat patients that have tested negative for HIV. However, it can also be effective in treating viral resistance, treatment failure, and patients with an HIV-1 RNA of 100,000 copies/ml or less."
Are there numerous facilities testing this in urban areas?
"There are a total of 36 enrolling sites for this clinical trial, which are situated in Denver, Birmingham, Los Angeles and 33 other cities. To make participation more convenient, it is best to select the location that is closest to you."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger